Atlas Trials

Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)

Clinical trial NCT06654336 · RECRUITING

Trial details

NCT number
NCT06654336
Sponsor
Ontario Clinical Oncology Group (OCOG)
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Prostate AdenocarcinomaCastration Sensitive Prostate Cancer
Start date
2026-03-30
Primary completion
2031-04-01
Enrollment
162

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.